IXICO CEO on strong FY26 - revenue up 28% and cash at £10.4m as TechBio strategy gathers pace

IXICO's FY26 revenue rose 28% with EBITDA beating upgraded guidance, fueled by its TechBio platform serving a 150+ program Alzheimer's/Parkinson's pipeline.

• Revenue up 28%: IXICO's FY26 results exceeded already-upgraded market expectations, with CEO Bram Gurdon noting EBITDA will land slightly above forecast and gross margin improved.
• Cash position £10.4m: Following a £10m capital raise in April, the company has invested in people and platform capabilities while maintaining financial discipline.

Themes, sentiment and reasons are AI-written paraphrases, checked so they never quote an episode. They may contain errors. Not investment advice. Episodes remain the property of their creators.